About half of the Omicron cases in a major hospital system in Texas have been among the vaccinated, according to a new study funded in part by the U.S. government.
Of those patients, 430 met the Centers for Disease Control and Prevention’s (CDC) definition of a breakthrough case, or a COVID-19 case that occurs among vaccinated people.
Most of the patients, 299, had received two doses of the Pfizer-BioNTech COVID-19 vaccine—the rest received either a Moderna primary vaccine series or the single-shot Johnson & Johnson vaccine.
The percentage of vaccinated patients was much higher for the Omicron variant than for the Alpha or Delta coronavirus variants, according to researchers.
The percentage jumped from 3.2 percent for Alpha to 24.1 percent for Delta to 49.9 percent for Omicron. All three strains are labeled as variants of concern (VOC) by the World Health Organization.
The study also found 85 patients who had gotten a vaccine booster dose, but still contracted symptomatic COVID-19.
Dr. James Musser, with Houston Methodist’s Center for Infectious Diseases, led the work with colleagues and experts from the Weill Cornell Medical College in New York and the University of Chicago. The study was funded by the Houston Methodist Academic Institute Infectious Diseases Fund, the National Institutes of Health (NIH), the National Institute of Allergy and Infectious Diseases, and the U.S. Department of Health and Human Services.
The study reads: “Several key findings were made, including (i) the Omicron VOC rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii) Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv) significantly fewer Omicron patients required hospitalization compared to Alpha and Delta patients; (v) the median length of stay for hospitalized Omicron patients was significantly shorter than for Alpha and Delta patients, and consistent with this observation, the maximum respiratory support required for Omicron patients was significantly less than for Alpha or Delta patients.”
Limitations on the study included samples only being obtained from patients with symptoms and the majority of cases in the Houston region not being included.
David Usharauli, co-founder and director of Tregeutix and a former NIH scientist who wasn’t involved with the research, wrote on Twitter that the study provided the “first direct evidence that #omicron infects unvaccinated and #vaccinated people similarly.”
“It is very different from both alpha and delta variants,” he wrote.
The CDC says breakthrough infections “are expected,” but that fully vaccinated people who get infected are less likely to develop serious illness when compared to unvaccinated people.
Early studies on the Omicron variant have signaled that primary vaccination series provide little protection against the variant, though the vaccines have held up fairly well against severe disease, as has natural immunity, or the protection gained from COVID-19 recovery.
In another study out after the New Year, researchers with NIH and health facilities in the Cleveland area have also found evidence that the Omicron variant is causing less severe illness by analyzing electronic health records from the TriNetX Analytics network.
“First time SARS-CoV-2 infections occurring at a time when the Omicron variant was rapidly spreading were associated with significantly less severe outcomes than first-time infections when the Delta variant predominated,” the study reads.
